ACBM · Acro Biomedical Co., Ltd. · Executive Compensation
$0.03
At close · Sep 7
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date of the financial statements being issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025, financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.56M
Shares
60.04M
Volume · Sep 7
66
Avg daily vol (2 sessions)
163
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jing-Zhou Chen | chief executive officer and chief financial officer | Appointed | 2026-09-02 |
| Jing-Zhou Chen | chief executive officer and chief financial officer | Appointed | 2026-09-02 |
| Shao-Hsiang Shih | director and as the Company's chairman | Appointed | 2026-09-02 |
| Yu-Ting, Su | director and as the Company's chairman and chief executive officer | Appointed | 2025-08-14 |
| Yu-Ting, Su | director and as the Company's chairman and chief executive officer | Appointed | 2025-08-14 |
| Yu-Ting, Su | director and as the Company's chairman and chief executive officer | Appointed | 2025-08-14 |
Leadership
- Jing-Zhou Chen CEO, CFO
- Yu-Ting, Su CEO, Chairman, Board Member
- Shao-Hsiang Shih Chairman
- Pao-Chi Chu Board Member